{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T07:29:18Z","timestamp":1745566158094,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.iac.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T20:03:27Z","timestamp":1714075407000},"page":"503-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Spontaneous Urticaria"],"prefix":"10.1016","volume":"44","author":[{"given":"Shyam R.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Anstey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2024.03.007_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The International EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2024.03.007_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaip.2018.04.012","article-title":"A\u00a0Comparison of the United States and International Perspective on Chronic Urticaria Guidelines","volume":"6","author":"Zuberbier","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.iac.2024.03.007_bib3","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jaip.2019.11.004","article-title":"Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis","volume":"8","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society","volume":"184","author":"Gon\u00e7alo","year":"2021","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.iac.2024.03.007_bib5","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jaip.2023.06.027","article-title":"Potential therapeutic approaches for chronic urticaria: beyond H1-antihistamines and biologics","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6 Pt 2","key":"10.1016\/j.iac.2024.03.007_bib6","first-page":"521","article-title":"The diagnosis and management of urticaria: a practice parameter part I: acute urticaria\/angioedema part II: chronic urticaria\/angioedema. Joint task force on practice parameters","volume":"85","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.iac.2024.03.007_bib7","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2024.03.007_bib8","article-title":"Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights","author":"Kovalkova","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2024.03.007_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jaip.2023.06.033","article-title":"Chronic urticaria and angioedema: masqueraders and misdiagnoses","volume":"11","author":"Bernstein","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.18176\/jiaci.0287","article-title":"Prevalence of drugs as triggers of exacerbations in chronic urticaria","volume":"29","author":"S\u00e1nchez","year":"2019","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2024.03.007_bib11","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.jaip.2020.06.057","article-title":"Clinical control of CSU with antihistamines allows for tolerance of NSAID-exacerbated cutaneous disease","volume":"8","author":"S\u00e1nchez","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.03.007_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.anai.2021.11.009","article-title":"Assessment of depression, anxiety, and stress in chronic urticaria and its correlation with disease severity","volume":"128","author":"Rani","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2024.03.007_bib13","article-title":"Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria","author":"Can","year":"2021","journal-title":"Asian Pac J Allergy Immunol."},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances","volume":"78","author":"Kaplan","year":"2023","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.iac.2024.03.007_bib15","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not viceVersa","volume":"11","author":"Xiang","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.03.007_bib16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2024.03.007_bib17","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/all.13832","article-title":"Increased expression of IL-24 in chronic spontaneous urticaria","volume":"74","author":"de Montjoye","year":"2019","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2024.03.007_bib18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2024.03.007_bib19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jaip.2023.05.039","article-title":"Positive basophil tests are linked to high disease activity and other features of autoimmune chronic spontaneous urticaria: a systematic review","volume":"11","author":"Mo\u00f1ino-Romero","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2024.03.007_bib20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/all.13352","article-title":"C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria","volume":"73","author":"Kolkhir","year":"2018","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.23822\/EurAnnACI.1764-1489.259","article-title":"Concomitant evaluation of d-dimer and C-reactive protein in chronic spontaneous urticaria may show divergent values","volume":"56","author":"Relvas","year":"2022","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2024.03.007_bib22","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaip.2022.11.016","article-title":"The benefit of complete response to treatment in patients with chronic spontaneous urticaria-CURE results","volume":"11","author":"Kolkhir","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaip.2020.08.055","article-title":"Comparative efficacy and acceptability of licensed dose second-generation antihistamines in chronic spontaneous urticaria: a network meta-analysis","volume":"9","author":"Phinyo","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2024.03.007_bib25","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jaip.2023.03.058","article-title":"Comparative safety profiles of individual second-generation H1-antihistamines for the treatment of chronic urticaria: a systematic review and network meta-analysis of randomized controlled trials","volume":"11","author":"Chaichan","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.03.007_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-023-00665-y","article-title":"The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials","volume":"24","author":"Xiao","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.iac.2024.03.007_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13601-017-0141-3","article-title":"Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria","volume":"7","author":"van den Elzen","year":"2017","journal-title":"Clin Transl Allergy"},{"author":"Dinesh","key":"10.1016\/j.iac.2024.03.007_bib28"},{"issue":"4","key":"10.1016\/j.iac.2024.03.007_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.03.007_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/all.13547","article-title":"Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study","volume":"74","author":"Metz","year":"2019","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.iac.2024.03.007_bib31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.iac.2024.03.007_bib32","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamadermatol.2021.3237","article-title":"Evaluation of pharmacologic treatments for H1 antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis","volume":"157","author":"Nochaiwong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.iac.2024.03.007_bib33","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"11","author":"Chuang","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.03.007_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.03.007_bib35","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jaip.2019.10.018","article-title":"High-dose omalizumab use in patients with chronic spontaneous urticaria","volume":"8","author":"Alizadeh Aghdam","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.03.007_bib36","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","article-title":"The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.03.007_bib37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/all.13675","article-title":"How to discontinue omalizumab in chronic spontaneous urticaria?","volume":"74","author":"T\u00fcrk","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.03.007_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaip.2019.07.021","article-title":"How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers","volume":"8","author":"T\u00fcrk","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.anai.2019.05.003","article-title":"Omalizumab for chronic urticaria in children younger than 12 years","volume":"123","author":"Al-Shaikhly","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.03.007_bib42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.03.007_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"Laburte","year":"1994","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.iac.2024.03.007_bib44","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1398-9995.2010.02419.x","article-title":"Cyclosporine-A in severe chronic urticaria: the option for long-term therapy","volume":"65","author":"Kessel","year":"2010","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2024.03.007_bib45","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jaip.2020.02.012","article-title":"Cyclosporine and omalizumab together: A new option for chronic refractory urticaria","volume":"8","author":"S\u00e1nchez","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2024.03.007_bib46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jaad.2011.06.004","article-title":"The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients","volume":"66","author":"Zimmerman","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2024.03.007_bib47","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jaip.2018.12.023","article-title":"Effectiveness and safety of oral tacrolimus in refractory chronic urticaria","volume":"7","author":"Dorman","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.03.007_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2018.3715","article-title":"Use of dapsone in the treatment of chronic idiopathic and autoimmune urticaria","volume":"155","author":"Liang","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.iac.2024.03.007_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anai.2013.09.028","article-title":"Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria","volume":"112","author":"Orden","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.03.007_bib50","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/0091-6749(91)90255-M","article-title":"Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria","volume":"88","author":"Jaffer","year":"1991","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2024.03.007_bib51","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1016\/j.jaip.2022.08.051","article-title":"Effectiveness of hydroxychloroquine and omalizumab in chronic spontaneous urticaria: a real-world study","volume":"10","author":"Khan","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:22:15Z","timestamp":1719361335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0889856124000298"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.03.007","relation":{},"ISSN":["0889-8561"],"issn-type":[{"type":"print","value":"0889-8561"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Spontaneous Urticaria","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}